2. Search Result
Search Result
Results for "

chemotaxis inhibitor

" in MedChemExpress (MCE) Product Catalog:

69

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

1

Inhibitory Antibodies

6

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124404
    12(R)-HETE

    		Na+/K+ ATPase Aryl Hydrocarbon Receptor Others Inflammation/Immunology
    12(R)-HETE is a metabolite of Arachidonic acid, AA (HY-109590) and can be found in skin from psoriatic lesions. 12(R)-HETE induces lymphocytes chemotaxis, stimulates calcium mobilization and chemotaxis in neutrophils via the BLT1 receptor, activates the aryl hydrocarbon receptor, and inhibits Na+/K+ ATPase activity in the corneal epithelium .
    12(R)-HETE
  • HY-P3982
    CKLF1-C19

    		CCR Inflammation/Immunology
    CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4 .
    CKLF1-C19
  • HY-124416
    ML604086
    1 Publications Verification

    		 CCR Inflammation/Immunology Endocrinology
    ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca 2+ concentrations .
    ML604086
  • HY-N8541
    Endocrocin

    		Endogenous Metabolite Inflammation/Immunology
    Endocrocin, an anthraquinone, is a fungal secondary metabolite. Endocrocin is a potent chemotaxis inhibitor with immunosuppressive properties .
    Endocrocin
  • HY-103360B
    trans-J-113863

    		CCR Inflammation/Immunology
    trans-J-113863 is a potent chemokine CCR1 and CCR3 receptor antagonist, and inhibits MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants with IC50 of 9.57 and 93.8 nM,respectively .
    trans-J-113863
  • HY-125567
    Antileukinate

    		CXCR Inflammation/Immunology
    Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury .
    Antileukinate
  • HY-123270
    RP23618

    		CCR Infection Inflammation/Immunology
    RP23618 is a non peptidic RANTES antagonist with the IC50 of 3 μM. RP23618 inhibit RANTES-induced chemotaxis of THP-1 cells .
    RP23618
  • HY-155300
    BLT2 antagonist-1

    		Leukotriene Receptor Inflammation/Immunology
    BLT2 antagonist-1 (compound 15b) is a selective BLT2 antagonist that inhibits the chemotaxis of CHO-BLT2 cells with an IC50 of 224 nM. BLT2 antagonist-1 does not inhibits the chemotaxis of CHO-BLT1 cells. BLT2 antagonist-1 also inhibits the binding of LTB4 and BLT2 with a Ki value of 132 nM. BLT2 antagonist-1 can be used for the research of the inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease .
    BLT2 antagonist-1
  • HY-116230
    BI-L-45 XX

    		Ser/Thr Protease Inflammation/Immunology
    BI-L-45 XX is an orally active anti-inflammatory agent. BI-L-45 XX can inhibit the release of neutrophil enzymes and chemotaxis, and is used in the study of adjuvant-induced arthritis .
    BI-L-45 XX
  • HY-159927
    TAK-661

    		CCR Inflammation/Immunology
    TAK-661 is a inhibitor of eosinophil chemotaxis. TAK-661 significantly reduces the bronchoconstriction during the late phase, along with the inhibition of eosinophilia in bronchoalveolar lavage (BAL) and the eosinophil infiltration into the airway wall .
    TAK-661
  • HY-122219
    R243
    1 Publications Verification

    		 CCR Inflammation/Immunology
    R243 is a potent and selective CCR8 antagonist. R243 inhibits CCL1/CCR8 interaction and inhibits CCR8 signaling and chemotaxis. R243 has antinociceptive and anti-inflammatory effects .
    R243
  • HY-109011
    Rosiptor
    3 Publications Verification

    AQX-1125

    		 Phosphatase Cancer
    Rosiptor (AQX-1125) is a selective and orally active phosphatase SHIP1 activator with anti-inflammatory effects. Rosiptor (AQX-1125) inhibits Akt phosphorylation, inflammatory mediator production and leukocyte chemotaxis in vitro .
    Rosiptor
  • HY-109011A
    Rosiptor acetate

    AQX-1125 acetate

    		 Phosphatase Cancer
    Rosiptor (AQX-1125) acetate is a selective and orally active phosphatase SHIP1 activator with anti-inflammatory effects. Rosiptor acetate (AQX-1125) inhibits Akt phosphorylation, inflammatory mediator production and leukocyte chemotaxis in vitro .
    Rosiptor acetate
  • HY-126536
    ChemR23-IN-1

    		Chemerin Receptor Inflammation/Immunology
    ChemR23-IN-1 (compound 2) is a ChemR23 inhibitor with IC50s of 38 nM and 100 nM for human and mouse ChemR23, respectively. ChemR23-IN-1 inhibits chemotaxis of CAL-1 triggered by Chemerin in vitro .
    ChemR23-IN-1
  • HY-123763
    MLN3126

    		CCR Inflammation/Immunology
    MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx .
    MLN3126
  • HY-17042A
    Cetirizine dihydrochloride
    2 Publications Verification

    P071

    		 Histamine Receptor Inflammation/Immunology Endocrinology Cancer
    Cetirizine dihydrochloride, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine dihydrochloride marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
    Cetirizine dihydrochloride
  • HY-17042
    Cetirizine
    2 Publications Verification

    		 Histamine Receptor Inflammation/Immunology Endocrinology
    Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
    Cetirizine
  • HY-103362
    CCR2 antagonist 4 hydrochloride
    3 Publications Verification

    Teijin compound 1 hydrochloride

    		 CCR Inflammation/Immunology
    CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific CCR2 antagonist, with IC50s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC50 of 24 nM .
    CCR2 antagonist 4 hydrochloride
  • HY-108323
    CCR2 antagonist 4
    3 Publications Verification

    Teijin compound 1

    		 CCR Inflammation/Immunology
    CCR2 antagonist 4 (Teijin compound 1) is a potent and specific CCR2 antagonist, with IC50s of 180 nM for CCR2b. CCR2 antagonist 4 potently inhibits MCP-1-induced chemotaxis with an IC50 of 24 nM .
    CCR2 antagonist 4
  • HY-164502
    NAP1051

    		Akt Cancer
    NAP1051 is a biomimetic analog of lipin A4 that achieves anti-tumor effects by targeting the inflammatory tumor microenvironment. NAP1051 inhibits neutrophil chemotaxis to fMLP and stimulates macrophage efferocytosis by activating AKT. NAP1051 can be used in colorectal cancer research .
    NAP1051
  • HY-100660A
    Cetirizine Impurity B dihydrochloride

    		Drug Metabolite Others
    Cetirizine Impurity B dihydrochloride is an impurity of Cetirizine dihydrochloride. Cetirizine, a second-generation antihistamine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
    Cetirizine Impurity B dihydrochloride
  • HY-100661
    Cetirizine Impurity D

    		Histamine Receptor Inflammation/Immunology Endocrinology
    Cetirizine Impurity D is an impurity of Cetirizine. Cetirizine, a second-generation antihistamine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
    Cetirizine Impurity D
  • HY-15724A
    Vercirnon sodium
    3 Publications Verification

    GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium

    		 CCR Inflammation/Immunology Endocrinology
    Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca 2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .
    Vercirnon sodium
  • HY-15724
    Vercirnon
    3 Publications Verification

    GSK-1605786; CCX282-B; Traficet-EN

    		 CCR Inflammation/Immunology Endocrinology
    Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca 2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .
    Vercirnon
  • HY-148853
    SRI-42127

    		HuR Others
    SRI-42127 is a HuR translocation inhibitor. HuR is an RNA regulator that binds to AREs, and HuR translocations promote the production of inflammatory cytokines in glial cells. However, SRI-42127 can destroy mRNA stability and inhibit gene promoter activation. SRI-42127 also inhibits microglial cell activation and attenuates recruitment/chemotaxis of neutrophils and monocytes .
    SRI-42127
  • HY-117896
    SC-50605

    		Leukotriene Receptor Inflammation/Immunology
    SC-50605 and SC-51146 are second-generation leukotriene B4 (LTB4) receptor antagonists that effectively inhibit LTB4-induced chemotaxis in guinea pigs. SC-50605 targets the LTB4 receptor and has the potential to inhibit inflammatory diseases such as asthma, rheumatoid arthritis, and skin diseases. .
    SC-50605
  • HY-119234
    CX4338

    		CXCR Inflammation/Immunology
    CX4338 is a CXCL8-mediated chemokine inhibitor with the activity of inhibiting CXCR2-mediated cell migration. CX4338 selectively inhibits CXCR2-mediated β-arrestin-2 recruitment and receptor internalization while enhancing CXCR2-mediated MAPK activation. CX4338 also inhibited CXCL8-induced chemotaxis, showing efficacy in CXCR2-overexpressing cells and human neutrophils. In vivo, CX4338 significantly reduced LPS-induced neutrophil numbers in mouse bronchoalveolar lavage fluid. The mechanism of action of CX4338 is to selectively inhibit CXCR2-mediated β-arrestin-2 activation, which is sufficient to inhibit CXCL8-mediated chemotaxis .
    CX4338
  • HY-153450
    JBI-589

    		Protein Arginine Deiminase Cancer
    JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research .
    JBI-589
  • HY-122536
    Ricinelaidic acid

    		Leukotriene Receptor Calcium Channel Endogenous Metabolite Inflammation/Immunology
    Ricinelaidic acid, a 12-hydroxy fatty acid，is a leukotriene B4 (LTB4) receptor antagonist with the Ki of 2 μM in porcine neutrophil membranes. Ricinelaidic acid inhibits chemotaxis and calcium flux induced by LTB4 in isolated human neutrophils (IC50=10 and 7 μM, respectively). Ricinelaidic acid inhibits bronchoconstriction induced by LTB4 in rats .
    Ricinelaidic acid
  • HY-17042AS
    Cetirizine-d4 dihydrochloride

    		Isotope-Labeled Compounds Histamine Receptor Inflammation/Immunology
    Cetirizine-d4 (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
    Cetirizine-d4 dihydrochloride
  • HY-17042S1
    Cetirizine-d8

    		Histamine Receptor Inflammation/Immunology
    Cetirizine-d8 is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
    Cetirizine-d8
  • HY-17042AS1
    Cetirizine-d8 dihydrochloride

    		Isotope-Labeled Compounds Histamine Receptor Inflammation/Immunology
    Cetirizine-d8 (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
    Cetirizine-d8 dihydrochloride
  • HY-17042S
    Cetirizine-d4

    		Histamine Receptor Inflammation/Immunology
    Cetirizine-d4 is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].
    Cetirizine-d4
  • HY-124668
    CCR1 antagonist 12

    		CCR Inflammation/Immunology
    CCR1 antagonist 12 (Compound 12) is an antagonist for CCR1 with IC50 of 3 nM for human CCR1. CCR1 antagonist 12 inhibits CCL3-induced transwell chemotaxis with an IC50 of 0.009 µM. CCR1 antagonist 12 exhibits good pharmacokinetic characters in rats model .
    CCR1 antagonist 12
  • HY-12807A
    FIPI hydrochloride

    5-Fluoro-2-indolyl deschlorohalopemide hydrochloride

    		 Phospholipase Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    FIPI hydrochloride is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI hydrochloride regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI hydrochloride can be used in cancer research. In addition, FIPI hydrochloride can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .
    FIPI hydrochloride
  • HY-12807
    FIPI
    4 Publications Verification

    5-Fluoro-2-indolyl deschlorohalopemide

    		 Phospholipase Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    FIPI is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .
    FIPI
  • HY-17042R
    Cetirizine (Standard)

    		Histamine Receptor Inflammation/Immunology Endocrinology Cancer
    Cetirizine (Standard) is the analytical standard of Cetirizine. This product is intended for research and analytical applications. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
    Cetirizine (Standard)
  • HY-17042AR
    Cetirizine (dihydrochloride) (Standard)

    		Histamine Receptor Inflammation/Immunology Endocrinology Cancer
    Cetirizine (dihydrochloride) (Standard) is the analytical standard of Cetirizine (dihydrochloride). This product is intended for research and analytical applications. Cetirizine dihydrochloride, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine dihydrochloride marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .
    Cetirizine (dihydrochloride) (Standard)
  • HY-116171
    (Rac)-Calpain Inhibitor XII

    		Proteasome Cardiovascular Disease Neurological Disease
    (Rac)-Calpain Inhibitor XII is a reversible and selective inhibitor of calpain I (μ-calpain, Ki=19 nM). (Rac)-Calpain Inhibitor XII has lower affinities for calpain II (m-calpain, Ki=120 nM) and cathepsin B (Ki=750 nM). (Rac)-Calpain Inhibitor XII has the potential for studying the role of calpains in diverse processes, including neutrophil chemotaxis, neuronal signaling, and cardiac response to injury .
    (Rac)-Calpain Inhibitor XII
  • HY-P99520
    Vilobelimab

    CaCP-29, IFX-1

    		 Complement System SARS-CoV Infection Inflammation/Immunology
    Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
    Vilobelimab
  • HY-N0634
    Cimifugin
    1 Publications Verification

    Cimitin

    		 NF-κB Inflammation/Immunology
    Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions . Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS .
    Cimifugin
  • HY-160998
    YM-344031

    		CCR Inflammation/Immunology
    YM-344031 is an orally active antagonist for CCR3. YM-344031 inhibits binding of Eotaxin-1 and RANTES to CCR3, with IC50 of 3.0 and 16.3 nM. YM-344031 inhibits ligand-induced rise in intracellular Ca [2+] and the ligand-induced chemotaxis. YM-344031 inhibits eotaxin-1-induced changes in eosinophil morphology in macaques blood, and prevents allergic skin reactions in a mouse allergy model .
    YM-344031
  • HY-13499
    JNJ-41443532

    CCR2 antagonist 5

    		 CCR Inflammation/Immunology
    JNJ-41443532 (CCR2 antagonist 5) is a selective, orally active hCCR2 inhibitor with good binding affinity (IC50=37 nM) and potent functional antagonism (chemotaxis IC50=30 nM). JNJ-41443532 displays a Ki of 9.6 µM for mCCR2 binding. JNJ-41443532 can be used in the research of inflammatory disease .
    JNJ-41443532
  • HY-145697
    GPR84 antagonist 2

    		GPR84 Inflammation/Immunology
    GPR84 antagonist 2 (compound 33) is a potent, selective, and orally active GPR84 antagonist (IC50=8.95 nM). GPR84 antagonist 2 shows improved potency in the calcium mobilization assay and the ability to inhibit the chemotaxis of neutrophils and macrophages upon GPR84 activation. GPR84 antagonist 2 has the potential for the research of ulcerative colitis .
    GPR84 antagonist 2
  • HY-123532
    JNJ10191584

    VUF6002

    		 Histamine Receptor Neurological Disease
    JNJ10191584 (VUF6002) is an orally active and selective histamine H4 receptor antagonist with a Ki value of 26 nM. JNJ10191584 shows 540-fold selectivity to H4 receptor over H3 receptor with a Ki value of 14.1 μM. JNJ10191584 inhibits chemotaxis of eosinophils and mast cells with IC50 values of 530 nM and 138 nM, respectively .
    JNJ10191584
  • HY-B0174A
    Olsalazine

    		Leukotriene Receptor Antibiotic Inflammation/Immunology
    Olsalazine is a potent inhibitor of macrophages chemotaxis to LTB4 with an IC50 value of 0.39 mM, also reduces the synthesis of 5-hydroxyeicosatetraenoic acid (5-HETE), 11-HETE, 12-HETE, and 15-HETE in polymorphonuclear leukocyte (PMNL) and mononuclear cells (MNL). Olsalazine can be used for researching ulcerative colitis. Anti-inflammatory activity .
    Olsalazine
  • HY-107558
    JNJ10191584 maleate

    VUF6002 maleate

    		 Histamine Receptor Neurological Disease
    JNJ10191584 (VUF6002) maleate (compound 40) is an orally active and selective histamine H4 receptor antagonist with a Ki value of 26 nM. JNJ10191584 maleate shows 540-fold selectivity to H4 receptor over the H3 receptor with a Ki value of 14.1 μM. JNJ10191584 maleate inhibits chemotaxis of eosinophils and mast cells with IC50 values of 530 nM and 138 nM, respectively .
    JNJ10191584 maleate
  • HY-125836
    CCR4 antagonist 2

    		CCR Endocrinology Cancer
    CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca 2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively .
    CCR4 antagonist 2
  • HY-103364A
    C-021 dihydrochloride
    2 Publications Verification

    		 CCR Inflammation/Immunology
    C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [ 35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
    C-021 dihydrochloride
  • HY-103364
    C-021
    2 Publications Verification

    		 CCR Inflammation/Immunology
    C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [ 35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
    C-021

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: